Genomic Study of Young-Onset Diabetes Mellitus

Launched by INDONESIA UNIVERSITY · Feb 15, 2024

Keywords

ClinConnect Summary

The "Genomic Study of Young-Onset Diabetes Mellitus" is a clinical trial aimed at understanding diabetes in young people in Indonesia. The study focuses on identifying genetic factors that could help in diagnosing different types of diabetes, particularly those diagnosed between the ages of 8 and 40. By using genetic testing, the researchers hope to find more accurate ways to diagnose young-onset diabetes and improve treatment options, which could lead to better health outcomes and fewer complications for patients.

To participate in this study, individuals must be diagnosed with diabetes according to specific guidelines, such as having high blood sugar levels, and must be between the ages of 8 and 40 at the time of diagnosis. Healthy volunteers in the same age range who have normal blood sugar levels are also welcome to join. Participants can expect to undergo genetic testing and provide information that could help researchers better understand diabetes in young people. This study is an important step toward personalized care for diabetes patients in Indonesia.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Diabetic patients
• * Diabetic patient fulfilling criteria from Indonesian Endocrinology Association (PERKENI) 2021 guidelines:
• • Fasting blood glucose 126 mg/dL
• • 2-hour post oral glucose blood glucose/oral glucose tolerance test 200 mg/dL
• • HbA1c 6.5%
• • Random blood glucose 200 mg/dL with classic symptoms or hyperglycemic crisis.
• • Patients aged 8-40 years old when diagnosed with diabetes mellitus
• • Registered in Dr. Cipto Mangunkusumo National General Hospital and satellite hospitals
• • Willing to participate in the study with proof of informed consent agreement
• Exclusion Criteria:
• • Subject is experiencing severe illness
• • Healthy controls Inclusion criteria
• • Aged 8-40 years old
• * Fulfilling criteria of normal blood glucose levels according to Indonesian Endocrinology Association (PERKENI) 2021 guidelines:
• • Fasting blood glucose 100 mg/dL
• • 2-hour post oral glucose blood glucose/oral glucose tolerance test 140 mg/dL
• • HbA1c 5.7% Exclusion criteria
• • Subject is unwilling to participate in the study